The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.
The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.
The user completed a Clascoterone study with no observable changes in hair loss and plans to try microneedling and Minoxidil next. They will microneedle weekly and apply Minoxidil twice daily, except on the night of microneedling, and compare results after six months.
The user experienced significant hair thickening after switching from three years of topical Minoxidil and keto shampoo to three months of topical finasteride and derma stamping. They also noted that they're using less than the recommended amount of finasteride, but still seeing great results.
KX-826 shows promise for hair maintenance at higher doses with minimal side effects, despite failing Phase III trials. The user believes it is more effective than Minoxidil, Finasteride, and RU58841.
The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.
The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.
The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
OP bought Koshine x826 and plans to update on its effectiveness, currently using fluridil. OP couldn't tolerate RU or DUT, while another user mixes Dutasteride with Koshine x826 weekly without side effects.
The user reports slight progress in hair growth after 3.5 months of using Kirkland Minoxidil twice daily and finasteride once daily, along with biotin and nioxin shampoo. They are pleased with the results and have experienced no side effects.
The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
The user reviewed the Kiierr 312 MD DualWave Laser for hair loss, using it alongside ketoconazole shampoo, Svvimer products, and oral finasteride. They also mentioned using minoxidil on their face and adjusting lifestyle factors like sleep, vitamin D, and protein intake.
The conversation is about someone who initially had positive results with Minoxidil for hair loss, lost those gains due to a hospital stay, and is now not seeing the same results upon resuming treatment. They plan to add microneedling and/or tretinoin to their regimen and are seeking success stories from others who did not respond to Minoxidil alone.
Using topical Minoxidil (Kirkland 5%) to treat thinning hair, with some users reporting positive results and others not seeing any effect. Other treatments mentioned include finasteride and adapalene gel.
Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.
The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.
Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.
The user has been using topical minoxidil with tretinoin for 9 months without much regrowth and suspects finasteride is responsible for any improvement. They are inquiring about tests to determine response to topical minoxidil and seeking advice on switching to oral minoxidil, including potential side effects and monitoring requirements.
The conversation discusses hair loss treatments, specifically using topical minoxidil, oral finasteride, ketoconazole, and derma stamping. Users share their experiences, with one noting improved scalp health and slight regrowth, while another considers switching treatments due to lack of progress.
The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.
The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.
The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.
The conversation is about the interest in testing verteporfin, potentially with a dermaroller, for hair loss treatment. There is frustration over the lack of group buys for promising treatments compared to past efforts with less evidence.